CVS Drops Lilly's Zepbound from Preferred Coverage in Novo Win
CVS Health Corp. 's drug-benefits unit negotiated a deal to make Novo Nordisk A/S 's Wegovy more widely available to its members, a blow to rival Eli Lilly & Co. 's Zepbound that was moved off the company's list of preferred drugs.
Starting July 1, Zepbound will no longer be preferred on CVS Caremark's standard formulary, while Wegovy and other anti-obesity medicines will be, according to the company. The change means that Lilly's drug may cost more to insurers or employers that opt to pay for weight-loss drugs and who use CVS Caremark to manage their prescription drug plans.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26
Ascendis Pharma A/S (NASDAQ:ASND) is among the 13 Biotech Stocks with Huge Upside Potential. It reported interim Week 26 data from its Phase 2 COACH Trial, confirming that combining TransCon hGH (lonapegsomatropin) with TransCon CNP (navepegritide) raised annualized growth velocity (AGV) and height Z-scores in children with achondroplasia. A close-up view of a hand manipulating a syringe while delivering TransCon CNP into a tumor. A mean AGV of 9.14 cm/year and a +0.53 Z-score rise were attained by treatment-naïve youngsters (N=12). Children (N=9) treated with TransCon CNP in the past achieved an AGV of 8.25 cm/year with a +0.44 Z-score improvement. The majority of side effects were modest, and safety remained consistent with monotherapies. The COACH Trial is the first to assess this combination in kids between the ages of two and eleven. While TransCon CNP is undergoing FDA priority review, TransCon hGH is approved as SKYTROFA® for juvenile growth hormone insufficiency. The treatment focuses on the FGFR3-CNP signaling imbalance that is at the heart of achondroplasia, a disorder that affects more than 250,000 people worldwide. It is anticipated that the results of week 52 and a scheduled Phase 3 trial in Q4 2025 will further clarify efficacy and long-term benefits. The biopharmaceutical business Ascendis Pharma A/S (NASDAQ:ASND) uses its TransCon technology platform to significantly improve patient outcomes. While we acknowledge the potential of ASND as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None.
New York Post
2 hours ago
- New York Post
Eating this Middle Eastern staple daily can lower your cholesterol: study
Give peas a chance! A little legume widely beloved in the Middle Eastern world can offer massive benefits to your heart, a new study has found. And the best part is that this versatile, beige gem is incredibly affordable and probably already in your pantry. Advertisement 3 A new study has found that a little legume widely beloved in the Middle Eastern world can offer massive benefits to your heart. Lorenzo Dottorini – The research — recently presented at the NUTRITION 2025 conference — identified chickpeas as the key to significantly lowering cholesterol and inflammation in people with pre-diabetes. More research would be needed to gain a larger sense of the health benefits, particularly in people who are not prediabetic. Advertisement The study included only 72 participants and lasted just 12 weeks, and the results were similar to eating white rice. However, the findings align with other research indicating chickpeas lead the way in heart-healthy foods. 3 The research identified chickpeas as the key to significantly lowering cholesterol and inflammation in people with pre-diabetes. – The hummus veg's high fiber content, particularly soluble fiber, is believed to bind with cholesterol in the digestive system and help flush it out of the body. Advertisement The fiber also promotes healthy gut bacteria and keeps the bowel moving, while chickpeas' low glycemic index can contribute to better blood sugar levels. Legumes in general can mimic the hunger-killing effects of drugs like Ozempic and Wegovy, thereby promoting weight loss by keeping you fuller for longer. A cup of chickpeas can deliver over 12.5 grams of fiber and nearly 15 grams of plant-based protein — all for under 270 calories. Advertisement They're also a rich source of iron, potassium and magnesium — essential nutrients that support overall health. The new study found that black beans had a similar effect on heart health, which is no real surprise. 3 Black beans are rich in antioxidants that help fight inflammation and may reduce the risk of chronic diseases. jitanong714 – A cup of cooked black beans provides about 15 grams of protein and 15 grams of fiber at under 230 calories. They're also rich in antioxidants — particularly anthocyanins, the same compounds that give blueberries their health rap — which help fight inflammation and may reduce the risk of chronic conditions like heart disease and cancer. Plus, black beans boast key nutrients like folate, iron, magnesium and potassium, which support everything from brain function to healthy blood pressure. 'The soluble fiber in these legumes helps to lower cholesterol by reducing how much is absorbed into the bloodstream,' registered dietitian Maddie Gallivan, who was not involved with the new study, told Medical News Today. 'When eaten as part of a diverse, plant-rich diet, beans and chickpeas can support a healthy gut microbiome.'
Yahoo
2 hours ago
- Yahoo
Domino's Pizza, McDonald's rating surprise tied to persistent consumer issue
Domino's Pizza, McDonald's rating surprise tied to persistent consumer issue originally appeared on TheStreet. Even the Hamburglar didn't see this one coming. Excessive weight has been a persistent problem in America, where at least one in five adults in each U.S. state is living with obesity, according to the Centers for Disease Control and Prevention. 💵💰💰💵 As obesity rates have risen, so have scientists' efforts to address this serious health issue, which can cause asthma, heart disease, stroke, type 2 diabetes and even some cancers. Early attempts to treat obesity came to the market as early as the 1930s. Amphetamines were the prevalent treatment in the 1940s and 1950s and demand continued into the 1990s. Glucagon-like peptide-1 agonists, which mimic the action of the naturally occurring hormone GLP-1, have been available for about two decades. GLP-1 medications, including Ozempic, Wegovy, Zepbound and Mounjaro, have been used for years to treat Type 2 diabetes, and studies have found that they are also effective at encouraging weight loss. Wegovy and Ozempic are manufactured by Novo Nordisk () , while Eli Lilly () makes Zepbound and Mounjaro. One investment firm says increased use of these medications could have serious implications for two of the biggest names in the fast-food industry: McDonald's () and Domino's Pizza () . The market for anti-obesity drugs, particularly those using injectable versions of GLP 1-based drugs, is still new and continuously evolving, Goldman Sachs said in a May 22 report. More Restaurants Beloved Mexican restaurant closing iconic location after 63 years Major restaurant chain quietly closes several locations Iconic restaurant closing its doors after 32 years The investment firm lowered its projections for such medication and now forecasts the global market to reach $95 billion by 2030. That's down from the previous estimate of $130 billion to reflect trends influencing how the drugs are priced, how long patients stay on them, and how patient populations are segmented. Goldman lowered its U.S. market projections to a peak of $70 billion, but the firm sees room for greater penetration in markets outside the U.S. Goldman forecasts a market peak of $50 billion outside the US, compared with $35 billion previously. A survey of more than 50 doctors in the US found that lower doses of anti-obesity medications are working well for a majority of patients and insurance coverage is the most important factor in the decision-making process, Goldman Sachs wrote. 'But to be clear, even with this moderated forecast, we see a significant growth opportunity for both existing players as well as new entrants into this market,' said Asad Haider, head of the health-care business unit within Goldman Sachs Research. Demand for GPL-1 drugs could dramatically hinder the food and restaurant industries, according to a study from Cornell's SC Johnson College of Business and the data firm Numerator. The report, entitled "The No Hunger Games," found that households with at least one user of GLP-1 drugs reduced its grocery spending by about 6% within six months of starting the drugs. The spending cut was as much as 9% for higher-income households. "We also find an 8.6% decline in spending at fast-food chains, coffee shops and limited-service restaurants," the study said. "Our findings highlight the potential for GLP-1 medications to significantly change food demand, a trend with increasingly important implications for the food industry as GLP-1 adoption continues to grow." The study warned that common side effects of GLP-1 medications, such as nausea, vomiting and gastrointestinal discomfort, have reportedly led to reduced adherence or discontinued use for some patients."Moreover, their long-term efficacy and safety remain areas of ongoing investigation," the report said. Redburn Atlantic analyst Chris Luyckx focused on the growing adoption of GLP-1 in recent research reports. Luyckx double-downgraded McDonald's to sell from buy with a price target of $260, down from $319. The analyst expects the GLP-1 weight-loss drugs to suppress consumer appetites and says they present an underappreciated longer-term threat for McDonald's. A 1% drag on sales today "could easily build to 10% or more over time," particularly for restaurant brands skewed toward lower-income consumers, the analyst tells investors in a research note. McDonald's stock was down about 1.3% at last check and is up 18.5% from a year ago. Redburn Atlantic also initiated coverage of Domino's Pizza with a sell rating and $340 price target. Domino's, the world's largest pizza chain, faces the heaviest pressure from adoption of GLP-1 weight loss drugs, with high exposure to dinner occasions and lower-income consumers, the firm said. Redburn Atlantic said the company's organic traffic remains weak, with carry-out far outpacing delivery. Challenged system-sales growth and elevated consensus expectations present downside risk for Domino's, the firm said. McDonald's closed regular trading on June 10 down 1.4% at $300.43. Domino's shares were off 2.7% at $ Pizza, McDonald's rating surprise tied to persistent consumer issue first appeared on TheStreet on Jun 10, 2025 This story was originally reported by TheStreet on Jun 10, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
